The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
Abstract
The protein product of the bcl‐2 gene is thought to be involved in inhibition of apoptosis; it may therefore be important in the modulation of hormonal/anti‐hormonal responsiveness exhibited by tumours. This study immunocytochemically investigates (i) relationships between bcl‐2 protein expression in primary breast cancers and other markers of prognostic and therapeutic value and (ii) associations of the bcl‐2 protein with breast cancer responsiveness to endocrine therapy. The bcl‐2 protein was found within the tumour epithelial cell cytoplasm of 32/46 breast cancer specimens; inter‐patient staining was heterogeneous. Immunostaining for steroid hormone receptors was strongly associated with that for the bcl‐2 protein, and it is thus possible that this protein, like progesterone receptor, is under oestrogen regulation via oestrogen receptor. The protein was inversely related to 2 markers of endocrine insensitivity, epidermal growth factor receptor (EGFR) and c‐erbB‐2 oncoprotein, while no associations were observed with either transforming growth factor (TGF)‐alpha or Ki‐67 proliferative status. A highly significant relationship was observed between response to endocrine therapy and the presence of bcl‐2 protein. Indeed, bcl‐2 immunostaining proved to be a more accurate predictor of response than oestrogen receptor status. Patients with elevated bcl‐2 immunostaining (particularly those who co‐expressed high oestrogen receptor levels) appeared to derive the greatest benefit from endocrine therapy. Our results are paradoxical since it was expected that the bcl‐2 protein would counteract the tumour inhibitory effects of endocrine therapies as it is thought to prevent programmed cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nuñez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., & Korsmeyer, S. J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3602 · Cited by 899
Cited by
Escaping Cell Death: Survival Proteins in Cancer
Jäättelä, M. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4455 · Cited by 611
Relationship between Schistosomiasis and Bladder Cancer
Mostafa, M. H., Sheweita, S. A., & O’Connor, P. J. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.97 · Cited by 530
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
Self-citationEndocrine resistance in breast cancer – An overview and update
Clarke, R., Tyson, J. J., & Dixon, J. M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.035 · Cited by 353
bcl-2: Role in epithelial differentiation and oncogenesis
Lu, Q.-L., Abel, P., Foster, C. S., & Lalani, E.-N. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90362-7 · Cited by 265
Metadata
- Authors
- Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., Willsher, P., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blamey, R. W., & Nicholson, R. I.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1994-12
- Volume
- 59
- Issue
- 5
- Pages
- 619-628
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W4249948852
- Cited by
- 160
- References
- 1
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. https://app.cochat.ai/papers/10.1002/ijc.2910590508
- The paper
- Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., Willsher, P., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blamey, R. W., & Nicholson, R. I. (1994). Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.2910590508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.